1.63

0.62% 0.010

Pre-market: 1.64 0.01 +0.61%

Inmune Bio Inc (INMB)

Overview News Price History Option Chain Financials Discussions Forecast

Inmune Bio Inc stock is traded at $1.63, with a volume of 526.91K. It is up +0.62% in the last 24 hours and up +15.60% over the past month. INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Previous Close:

$1.62

Open:

$1.58

24h Volume:

526.91K

Relative Volume:

0.87

Market Cap:

$43.33M

Revenue:

$50,000

Net Income/Loss:

$-41.60M

P/E Ratio:

-0.9619

EPS:

-1.6946

Net Cash Flow:

$-20.20M

1W Performance:

+14.79%

1M Performance:

+15.60%

6M Performance:

+4.49%

1Y Performance:

-29.44%

1-Day Range:

$1.58

$1.71

1-Week Range:

$1.30

$1.71

52-Week Range:

$1.09

$3.244

Inmune Bio Inc Stock (INMB) Company Profile

Name

Inmune Bio Inc

Sector

Healthcare (1095)

Industry

Biotechnology (614)

Phone

(858) 964-3720

Address

225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA

Employee

Twitter

@INmuneBio

Next Earnings Date

2026-08-06

Latest SEC Filings

INMB's Discussions on Twitter

Compare INMB vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INMB Inmune Bio Inc	1.63	37.75M	50,000	-41.60M	-20.20M	-1.6946
VRTX Vertex Pharmaceuticals Inc	496.73	124.70B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	623.54	66.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	927.77	55.17B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.03	38.90B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	187.28	38.71B	742.00K	-1.37B	-1.07B	-7.0731

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-01-25	Downgrade	BTIG Research	Buy → Neutral
Jul-01-25	Downgrade	Scotiabank	Sector Outperform → Sector Underperform
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Oct-21-24	Initiated	Alliance Global Partners	Buy
Sep-27-24	Initiated	Raymond James	Outperform
Aug-22-24	Initiated	Scotiabank	Sector Outperform
Jun-01-23	Initiated	Robert W. Baird	Outperform
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-21-21	Initiated	B. Riley Securities	Buy
Jan-22-21	Reiterated	Maxim Group	Buy
Sep-01-20	Initiated	BTIG Research	Buy
Jul-15-20	Reiterated	H.C. Wainwright	Buy

View All

Inmune Bio Inc Stock (INMB) Latest News

Jun 30, 2026

Price to sales forward of INmune Bio Inc. – NASDAQ:INMB - TradingView

Jun 30, 2026

Price to earnings forward of INmune Bio Inc. – NASDAQ:INMB - TradingView

Jun 30, 2026

Jun 29, 2026

INmune Bio Inc.(NasdaqCM:INMB) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Dynamic Index - marketscreener.com

Jun 29, 2026

INmune Bio Inc.(NasdaqCM: INMB) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Enterprise value to EBIT forward of INmune Bio Inc. – NASDAQ:INMB - TradingView

Jun 29, 2026

INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000E Index - marketscreener.com

Jun 29, 2026

INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Index - marketscreener.com

Jun 29, 2026

INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Enterprise value to EBITDA forward of INmune Bio Inc. – NASDAQ:INMB - TradingView

Jun 28, 2026

Jun 27, 2026